There is an unprecedented level of support among regulators to advance the adoption of decentralized clinical trials, yet companies that undertake this mode of research need to be mindful of some of the challenges that can derail these efforts.
Sponsors should keep their computer systems secure, closely adhere to patient privacy laws, as well as follow good clinical practices and adopt flexible uses of technology to ensure data can be collected remotely.
So asserted two experts in the field of decentralized research who discussed their perspectives on how to make these types of trials work at a June 21 the meeting of the Drug information Association in Chicago.
“Health related data are targets … ransomware is occurring, and phishing attempts is a real and present danger that can bring organizations to their knees,” said Jonathan Andrus, president and COO of Clinical Research IO (CRIO), who along with Megan Petrylak, executive vice president of Clinical Ink, shared their viewpoints on overcoming challenges to decentralized research.
